Le Lézard
Classified in: Health, Science and technology
Subjects: Webcast, Advisory

QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast


QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022.

Press release date / time: Wednesday, July 27, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, July 28, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.

Three options for joining the conference call

Register for call back connection

 

Click here:

Connect Me

 

Service available 15 minutes before call start

Dial-in by phone

 

 

+1 646 828 8075 (U.S.)

+44 (0)330 165 4012 (UK)

+49 (0)69 22222 5197 (GER)

 

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

 

Conference ID: 3332305

 

Access the audio webcast

 

Click here:

Access Webcast

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1556677&tp_key=b55d95ed6e

Contact: [email protected]

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.


These press releases may also interest you

at 07:07
At least 5% of Americans suffer from chronic low back pain. [1] Over $630 billion is spent annually on costs to society [2], and chiropractic care is essential in managed post-surgical spinal pain [3] and scoliosis [4]. To prepare clinicians...

at 07:00
Ziegler is pleased to announce the successful closing of Shenandoah Valley Westminster-Canterbury's $71,000,000 Series 2022A and 2022B Bonds for the Senior Living Finance Practice. Shenandoah Valley Westminster-Canterbury (SVWC) is a Virginia...

12 aoû 2022
The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of LifeStance Health Group, Inc. common stock issued in connection with LifeStance Health's June 10, 2021 initial...

12 aoû 2022
An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and...

12 aoû 2022
Core One Labs Inc. , , (the "Company" or "Core One") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. ("Awakened") have successfully produced a precursor that can be...

12 aoû 2022
Following the passage of the Inflation Reduction Act, Peter L. Saltonstall, President and CEO, the National Organization for Rare Disorders (NORD), issued the following statement:...



News published on 7 july 2022 at 06:05 and distributed by: